Literature DB >> 17077157

Three months treatment of active spondyloarthritis with imatinib mesylate: an open-label pilot study with six patients.

K K Eklund, A Remitz, H Kautiainen, S Reitamo, M Leirisalo-Repo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17077157     DOI： 10.1093/rheumatology/kel365

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  4 in total

1.  Imatinib inhibits CSF1R that stimulates proliferation of rheumatoid arthritis fibroblast-like synoviocytes.

Authors:  X Hu; J Tang; X Hu; P Bao; J Pan; Y Ou; W Deng; Y Liang
Journal:  Clin Exp Immunol       Date:  2018-10-23       Impact factor: 4.330

2.  Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice.

Authors:  Cédric Louvet; Gregory L Szot; Jiena Lang; Michael R Lee; Nicolas Martinier; Gideon Bollag; Shirley Zhu; Arthur Weiss; Jeffrey A Bluestone
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-17       Impact factor: 11.205

3.  IL-17 in spondyloarthritis: is the T-party over?

Authors:  Nataliya Yeremenko; Dominique Baeten
Journal:  Arthritis Res Ther       Date:  2011-06-24       Impact factor: 5.156

4.  A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis.

Authors:  Jacqueline E Paramarta; Maureen C Turina; Troy Noordenbos; Tanja F Heijda; Iris C Blijdorp; Nataliya Yeremenko; Dominique Baeten
Journal:  J Transl Med       Date:  2016-10-27       Impact factor: 5.531
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.